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1. General Background   
 
1.1   Introduction  
 
The relative roles of environmental and genetic components in the causation of many 
diseases, especially cancer, have been extensively investigated over the last 20 years.  
Some cancer types are known to have a larger genetic component than others. 
In the NHL-BFM Study Center, several single case observations have been made that 
substantiated the suspicion, that there may be heritable components in the development 
of childhood NHL. 
 
In Germany, non-Hodgkin lymphomas (NHL) are the third
12
 most common type of can-
cer in children. While the incidence of adult NHL in Germany 
1
 and most Western 
countries
24, 25, 5
 has risen over the past several decades, the age-adjusted incidence of 
NHL in childhood remained quite stable.
 12, 5
 
Some studies suggest that the risk of NHL might be elevated among individuals with a 
family history of malignant diseases, especially hematopoietic cancers.
 29, 4 
Zhu et al
29
 found an association between NHL and the family history of hematologic 
malignancies or lymphoma.
 
Individuals diagnosed with lymphoma exhibited a three 
times greater possibility of other family members also being diagnosed with lymphoma 
(odds ratio [OR]=3.0, 95 percent confidence interval [CI]=1.7-5.2). Furthermore, sub-
group analyses showed an increased risk for hematologic cancers (OR=2.0, 95 % 
CI=1.2 – 3.4) .29 
Several case-controls studies with malignant lymphoma
4, 28
 reveal that a history of hem-
atopoietic malignancy in a first-degree relative is associated with higher risk of NHL 
(OR=1.8, 95% CI = 1.2 - 2.5)
 
(Chang et al) 
4
  
Relative risk rates were even higher in association with hematopoietic cancer in siblings 
(OR = 3.2, 95 % CI = 1.3 - 7.6).
 4
 
Zhang et al. subdivided the increased risk of NHL in relatives of patients with hemato-
poietic malignancy into risks for NHL in first-degree relatives of patients with lympho-




In a large study composed of 10211 NHL cases and 11905 controls, Wang et al con-
firmed in 2007 that the risk for NHL is elevated among first degree relatives of patients 
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with NHL, Hodgkin’s disease and leukemia. Relative risk was highest in relatives of a 




Despite these compelling data, most of these studies only assessed the risk of NHL in 
adulthood- there is little data investigating potential familial predisposition for child-
hood NHL.  
 
NHL in childhood differs considerably from NHL in adults. The majority of pediatric 
NHL cases are Burkitt lymphoma, precursor-T-cell and precursor B-cell lymphoblastic 
lymphoma, and anaplastic large cell lymphoma, all rare in adult NHL types.
 3, 17 
In con-
trast, the main NHL subtypes in adults, follicular lymphoma, diffuse large B-cell lym-
phoma, chronic lymphocytic leukemia (CLL) and plasma cell neoplasm are exceedingly 
rare in childhood. 
Le Bihan et al reported in 1996 a small, not statistically significant excess of hematolog-
ical malignancies in families of children with NHL.
 16 
In a case control study that in-
cluded 163 pediatric NHL cases, a familial history of cancer was linked to an increased 




However, these studies were comprised of small cohorts of pediatric NHL patients fol-
lowed for only a short period of two years, or from a single institution. Due to these 
limitations, analysis of biologically distinct childhood NHL subtypes was compromised. 
  
A study of distinct NHL subtypes is warranted however, since strong evidence, such as 
differences in sex ratios and specific age peak incidence rates, suggest etiologic hetero-
geneity. 
 
While the increasing rate of adult NHL suggests there is an influence of environmental 
factors (such as HIV or obesity), the stable rate of NHL in childhood may be a better 




Although the etiology of NHL is largely unknown, some risk factors do increase the risk 
of NHL. Inherited immune deficiency
18
 is a strong risk factor to develop childhood 









Furthermore, immunosuppressive therapy or infectious diseases, such as HIV or EBV, 
are also strong risk factors for pediatric NHL.





reported that in children with mature B-cell lymphoma, another NHL 
was the most common secondary malignant neoplasm (SMN) following successful 
treatment of their primary non-Hodgkin lymphoma.
 26
 This may be a further indication 
of familial predisposition, as in most other childhood cancers, acute myelogenous leu-
kemia/ myelodysplastic syndromes (AML/MDS) and central nervous system tumors list 




While most genetic content is identical between humans, there are many sites with pos-
sible variations (polymorphisms).These are referred to as ‘Single Nucleotide Polymor-
phisms’ (SNPs). SNPs are single base pair sites in the human genome where more than 
one base can occur in the population. To qualify as a SNP, the variant base must exist in 
more than > 1 percent of the gene pool of a population group. More than 5 million SNPs 
are documented in the human genome thus far. 
These variations can result in different gene products and/or transcription factor binding 
site sequences, and occasionally correlate with specific (immune-) responses during an 
infection or allergic reaction. For example, Lan et al
15
 showed, that SNPs within cyto-
kine genes (essential for the regulation of the immune response), particularly interleu-
kins (IL) IL-4,IL-5,IL-6 and IL-10,  are associated with an increased risk of NHL. In 
this study, analysis of the IL-10 promoter region revealed an increased risk for B-cell 
lymphomas in persons with the AGCC haplotype (Haplotype= sequence of SNPs on 
one single DNA strand) (OR = 1.54, 95 % CI = 1.21-1.96) as well as the TATA haplo-
type (OR = 1.37, 95 % CI = 1.05-1.79). 
Likewise, an increased risk for T-cell lymphoma was associated with other SNPs in the 
IL-4 region.
 15 
The existence of genetic factors linked to NHL may indicate the existence of multiple 
genetic predispositions for NHL. Once a genetic predisposition has been established, a 




NHL is not a single homogenous disease. There are three large groups: the (precur-
sor/mature) B-cell-, (precursor/mature) T-cell- and natural killer cell lymphomas. Bur-
kitt’s lymphoma and follicular lymphoma (FL) are for example common mature B-cell 
lymphomas, whereas anaplastic large cell lymphomas (ALCL) represent a subtype of 
mature T-cell lymphomas (Appendix #3). The various NHL entities biologically differ 
widely. It is possible, perhaps even likely, that different genetic components may be 
relevant for only specific NHL subtypes. 
 
The NHL-BFM Study Center has a large patient collection, which uses a standardized 
categorization of NHL for patients under the age of 15. This collection has more than 
2500 patients, and offers an excellent possibility to pursue the question of whether, 
there is a familial predisposition to NHL in childhood. 
 
1.2   Goals 
 
The NHL-2007 study aimed to determine if there is an excess of malignancies, especial-
ly lymphoid malignancies, in first, second, and third degree relatives of childhood NHL 
patients for the entire group, as well as for distinct biological subgroups of childhood 
NHL. The specific goals were: 
 
 Detection, of whether an excess of malignancies occur in first- to third degree 
relatives. 
 Detection, of whether an excess of childhood cancers (under the age of 15) oc-
cur in these relatives. 
 Detection, of whether an excess of childhood NHL (under the age of 15) occurs 
in these relatives. 
 Identification of high risk groups. 
 Determination of whether different NHL subtypes are associated with different 
risk factors. 
 
If familial predisposition for childhood NHL exists, or for a distinct subtype of NHL 
can be confirmed, this provides the basis for directed research aimed to identify the pre-
disposing (e.g. genetic) factors.  
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Beyond the possibility of gaining new scientific insight into the pathogenesis of child-
hood NHL, identification of predisposing risk factors would be of great benefit to future 
patients and their families.  
Knowledge of predisposing factors would provide the opportunity to identify children at 
high risk and to initiate early medical interventions in these children designed to detect 
NHL at an early stage. Also if familial clustering is proven, screening of siblings, cous-
ins and offspring of (former) NHL patients may also be warranted.  
 
2. Material and Methods  
 
2.1   Pilot Study 
 
To retrieve data from families of former patients with childhood NHL, a special ques-
tionnaire was developed. (See appendix #1) 
A pilot study was designed to determine if the questionnaire was an adequate instrument 
to collect all needed data to ascertain whether there is a familial predisposition to Non-
Hodgkin-Lymphoma in childhood and adolescence. 
After approval by the ethics committee, the questionnaire was tested in a study, com-
posed of 98 former pediatric oncology patients, who were treated at the Children’s Hos-
pital in Giessen since 1981.   
The rate of return and accuracy of reported items should conduce as a measurement for 
this question. 
The primary goal of the pilot study was to determine rate of return. A return rate of 60 
% was defined as sufficient. A secondary goal was to test the completeness and correct-
ness of reported items per named person. Greater than 80 % of items per person com-
pleted correctly was defined as sufficient. 
 
2.1.1 Participants included 
 
The questionnaire was sent to 98 former childhood cancer patients and/or their families. 
These 98 patients were treated between 1981 and 2006 in the department of hematology 





2.1.2 Implementation of the pilot study 
 
The former patient and/or parents obtained the questionnaire, a briefing about the study, 
informing them, that participation was voluntarily, a consent form, and instructions de-
tailing how to complete the questionnaire. A stamped envelope to return the data to the 
NHL-BFM study center was also enclosed. 
To protect patient anonymity, the questionnaire listed only an individual patient identi-
fication number and the date of birth of the former patient on it.  
The former patient/ parents were asked to complete the questionnaire and return it to the 
NHL-BFM study center within six weeks after receipt. 
We evaluated, which completed fields were adequate for analysis. 
Former patients or, parents who participated were subsequently surveyed a short tele-
phone interview regarding their opinion about the comprehensibility and clarity of the 
questionnaire. They were also asked if they had difficulty filling in the questionnaire or 
had other suggestions for improvement.  
 
2.1.2.1 Data management 
 
With the structured questionnaire, data were gathered, made anonymous, and subse-
quently put into a database. Neither names nor data with any personal information were 
saved, but merely assessed as analyzable or non-analyzable answers per named person 
and these fields were tallied. Common sources of errors were also ascertained, docu-
mented and analyzed.  
The following software applications were used: 




2.1.2.2 Ethics and legal aspects 
 
The study was approved by the ethics committee of the Faculty of Medicine of the 
Justus Liebig University, Giessen. 
It was made clear to all subjects, that they are free to quit the study at any time, without 
disclosure of their reason for withdrawal. It was also explained, that data would only be 
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saved in anonymous format. Only questionnaires accompanied by a signed consent 
form were evaluated. As purpose for data protection, all personal data have been de-
stroyed. 
 
2.2  Modification of the questionnaire 
 
As a consequence of the results from the pilot study, three structural modifications and 
more than ten alterations in the particular sections were made to improve the question-
naire beyond the pilot. (See appendix #2) 
 
2.2.1 Structural modifications 
 
A family tree was pictured on the first page of the questionnaire. This pedigree showed 
all family members for which we sought information and their allotted number of sec-
tion, so the respondent could easily visualize their family structure. 
Furthermore all frames surrounding the different sections were in bold, so respondents 
could see which family members the questions referred to. 
The questionnaire was reorganized, such that all subunits were entirely displayed on one 
page, with no paginations within the sections. 
 
2.2.2 Alterations within the Sections 
 
In each section, phrases pointing out which relative the questions referred to were 
changed from ‘(…) child, who has had cancer’ (‘(…) an Krebs erkrankten Kindes’) to 
‘(…) child, who has had lymphoma (patient)’ (‘(…) ehemals an Lymphom erkrankten 
Kindes (Patient)’). This change was made because some families had more than one 
child with cancer. This was confusing to respondents, since in many cases parents or 
other family members complete the questionnaire, rather than the former patient. 
 
In response to weaknesses identified in the pilot questionnaire, queries for: ‘deceased 
yes/no’, year of birth, and ‘cancer yes/no’ were changed to bold letters. 
The query that concretes which persons exactly deceased has been extended to ask for 
the first name and the consecutive number of the chart to diminish any equivocality. 
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Section 3 asks about nieces and nephews of the (former) patient. This section was con-
fusing to several respondents. To help participants identify the correct family structure, 
the italic amendment ‘children of siblings of the patient’ (Kinder von Geschwistern des 
Patienten) was made. 
Similar explanations were added to sections 5 and 6, concerning aunts and uncles of the 
(former) patient. 
Additional rows were also added, providing more space to fill in relatives of large fami-
lies. Three rows were added for siblings, two rows for nieces and nephews, six rows for 
maternal and paternal aunts and uncles, and another six rows for maternal and paternal 
cousins.  
 
A checklist (appendix #6) was developed, to verify that essential items have been com-
pleted. For instance, the respondent is asked within each section whether any family 
members are deceased. The checklist was designed to diminish specific oversights 
which were seen in the pilot questionnaire. 
The pilot questionnaire included questions concerning grandparents of the (former) pa-
tient. During planning for the NHL-2007 study, epidemiological considerations revealed 
that data regarding grandparents of the (former) patient might not be analyzable for the 
research project. 
The concern with evaluating grandparents is that it is not epidemiologically possible to 
create an appropriate comparison group for this age range. It is difficult to assess if 
grandparental cancers in that age range display a statistically significant enrichment or 
not. Since grandparental data appeared to not be evaluable, the German Childhood Can-
cer Registry recommended removing the section regarding grandparents of the (former) 
patient from the NHL-2007 questionnaire. 
An additional alteration was made in the section regarding the index patient himself. A 
question which asked whether the (former) patient him-/herself had an immune defi-
ciency syndrome (detailed in an enclosed list of immune deficiencies) was added. Other 
family members were already queried about immune deficiencies in the pilot question-
naire. 
Furthermore a question asking if the (former) patient him-/herself was a twin or triplet, 
was extended to include whether he/she might have been a quadruplet or quintuplet. 
For practical reasons, the consent form was moved to the first page of the questionnaire. 
This simplified removal of the consent form from the stapled questionnaire without tak-
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ing it apart. It also expedited checking whether the consent form had been signed. 
Signed consent forms were then removed immediately upon receipt without damaging 
the remaining questionnaire and stored separately to guarantee anonymity. 
 
The sequence of sections was changed to provide a more coherent questionnaire. After 
the sections 1-4 regarding the immediate family of the (former) patient, questions about 
extended family (aunts, uncles and cousins) of the (former) patient moved to sections 5-
8. Sections 5 (S5) and 6 (S6) comprise questions regarding maternal aunts and uncles 
(S5) or paternal (S6). Sections 7 (S7) and 8 (S8) contain questions regarding maternal 
(S7) and paternal (S8) cousins of the (former) patient. 
Maternal and paternal cousins each have their own separate page. At the end of each 
page for cousins, the participant is asked to verify whether information regarding their 
cousins is complete.  
 
The questionnaire was extended with an annex in triplicate, allowing respondents to fill 
in all possible information about lymphoma or leukemia in family members. This annex 
is in triplicate in an attempt to diminish mistakes between family members. For every 
family member, with any leukemia or lymphoma, there is one page dedicated for com-
pletion of all information about that particular relative and their specific cancer. This 
annex specifically requests for information to differentiate between Hodgkin/Non-
Hodgkin-Lymphoma, acute or chronic leukemia, and lymphocytic or myelocytic leu-
kemia. 
 
2.3 Development of the Study protocol 
 
2.3.1 Participants included 
 
Participants were former patients with NHL during childhood aged 0-15 at diagnosis 
who were enrolled into the cooperative, multicenter studies (ALL/NHL-BFM 86, NHL-
BFM 90, NHL-BFM 95, ALCL 99, B-NHL-BFM  04, EURO-LB 02) between 1986 and 
2007 in Germany. All patients were (re)classified according to the World Health Organ-
ization Classification of hematological Malignancies. 
11 
(See appendix #3) Patients with 
NHL as second malignant neoplasm were included even if their first childhood cancer 
was not NHL. 
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In total, 2449 of 2679 (former) patients with childhood NHL met these criteria. Two-
hundred thirty patients were excluded, because they were > 16 years old at their time of 
diagnosis (Table 1). 
Also excluded were all (former) patients who refused contact or the hospital advised not 
to contact because of special problems. Patients who had moved abroad and could not 
be contacted were likewise omitted. A final patient was excluded due to his participa-
tion in a prior study in 2008

.  
Former patients/their families were contacted via two different ways: 
The German Childhood Cancer Registry (GCCR) contacted 2061 (former) patients or a 
member of their family. The NHL-BFM study center attempted contact with an addi-
tional 242 participants in cooperation with 54 German hospitals. 
 
Table 1:  Survey Participants – Included/Excluded 
Participant / Details Number of Patients 
  
Total (former) NHL patients 2679 
Excluded  376 
   Excluded >= 16 years of age at       
   diagnosis  
230 
   Excluded because of special problems 142 
Excluded due to correction of diagnosis 
(no NHL) 
3 
   Excluded due to participation in another   




   Contacted by:   GCCR  2061 
   Contacted by:   NHL-BFM 134  




                                                 

  According to the “Gesellschaft für Pädiatrische Onkologie und Hämatologie” (GPOH), (former) patients 





2.3.2 GCCR and NHL-BFM Study Center  
 
German Childhood Cancer Registry 
The German childhood cancer registry was founded in 1980 and collects data from 
nearly all newly-detected cancer cases diagnosed before the age of 15 years in Germa-
ny. 
Only about 1% of families refuse consent to named registration and follow-up. Besides 
serving as population based-registry, the GCCR also collects clinical data, such as stag-
ing and grading. Most cases have follow-up for status and current address.  
Cases pertaining to patients of age15 years or above are registered with minimal infor-
mation (this includes their address), if reported, which is the case for most participants 
in clinical studies. 
Besides these routine analyses, the GCCR is also engaged in studies concerning public 
health issues, including survival analyses, regional analyses, and studies on life quality 
after childhood cancer. 
 
NHL-BFM Study Center 
 
 
The NHL-BFM study center is a registry with central classification for all subtypes of 
Non-Hodgkin Lymphoma diagnosed in children and adolescents. It is study center for 
cooperative multicenter therapeutic studies in Germany, Austria and Switzerland.   
From 1986 to 2007, NHL-BFM collected comprehensive data on 2575 children and 
adolescents (age 0-18) diagnosed with NHL in Germany an enrolled into studies 
ALL/NHL-BFM 86, NHL-BFM 90, NHL-BFM 95, ALCL 99, B-NHL-BFM  04, EU-
RO-LB 02 
All patients were classified according to the WHO-based classification
11
 with central-
ized pathologic review of more than 90-% of cases. 
According to GCCR data, since 1987 over 95 % of children under 15 years and diag-




2.3.3 Ethics and legal aspects 
 
An affirmative vote by the Committee for research on late effects of the ‘Deutsche Ge-
sellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)’ was obtained in July 
2007. (Appendix 4) 
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Furthermore, approval by ethics committee of the faculty of medicine, JLU Giessen was 
obtained in August 2007. (Appendix 5) 
All subjects were aware, they could quit the study at any time, without disclosure of 
their reason for study withdrawal. Only questionnaires with a signed consent form were 
evaluated.  The questionnaires do not contain any identifyinga information about partic-
ipants. The original questionnaires are stored in the ‘Zentrum für Kinder- und Jugend-
medizin, Abt. Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Giessen’ 
for 30 years. The databases are stored in the German Childhood Cancer Registry in 
Mainz for 30 years. 
 
2.3.4 Development and modification of work schedule 
 
To organize the NHL-2007 study and conduct this project, a work flow algorithm com-
prised of ten steps (demonstrated in figure 1) was developed. This diagram reflects all 
steps after successful completion of pilot study and implementation of the final version 
of the questionnaire.  
 
 
Figure 1: 10 Steps - Work flow algorithm 
 
Step1 NHL 2007 database 
and its interfaces  
(GCCR) 
Step2 Retrieving patients 
data from several  
NHL-Databases 
(NHL-BFM/GCCR) 
Step3a Sending out the 
Questionnaires 
 (GCCR) 




Step5 Collection of questionnaires  








Step5a Potential 2nd contact 
for detailed information if a 
hematol. malignancy has 
been reported  
(NHL-BFM) 
Step6 Data verification  
& Revision  
(NHL-BFM) 
Step7 Cooporation with other CRs 
Statistical analysis plan 
Step8 Data cleaning 
(GCCR/NHL-BFM)  
Step9 Statistical analysis 
(GCCR/NHL-BFM) 
Step10 Dissertation & 






2.4 Development and testing of the database  
 
Fundamental to this project was the development of a database (figure 1, ‘Step1’), in-
cluding all the necessary data from the NHL-BFM and GCCR data bases, as well as all 
data from the questionnaire. Creation of this database was realized in close cooperation 
with a GCCR programmer. 
Over several months different database versions were developed and tested until the 
final ‘NHL-2007’ database was completed. To minimize data input oversights, the entry 
mask was designed nearly identical to the final study questionnaire.  
The database included several primary plausibility checks, already active while data 
were entered. These plausibility checks guide data entry and prevent basic typograph-
ical mistakes, such as transposed digits.  
When errors occur, they are immediately detected and corrected while the data are en-
tered. The NHL-2007 database only collected data. Consequently, for the following 
analyses, data were transferred from the NHL-2007 database to SAS. 
The database and plausibility checks were programmed in MS Access, with interfacing 
to the SAS program programmed in sql.  
For programming and data entry, notebooks built using the ‘Windows XP’ and ‘Win-
dows Office 2000’ platforms were created. 
The following data were extracted from the NHL-databases and transferred to the‘NHL-
2007’ study database (figure 1, ‘Step2’): gender, date of birth, date of first diagnosis, 
NHL subtype, immunodeficiency status and if the patient and relatives had a second 
malignant neoplasm (SMN), and if so, the type of SMN. 
The database was programmed such that persons entering data into the NHL-2007 data-
base were not able to access patient-related data that were extracted from the NHL-
databases.  
 
2.4.1 Data transfer into the database 
 
Human errors cannot be extinguished completely. But to reduce the risk of accidentally 
hitting the wrong keys, all data entered in the NHL-2007 database was controlled and if 





2.5   Sending out the questionnaires via GCCR 
 
The GCCR and NHL-BFM Study Center were used as sources to contact almost all 
cases enrolled in NHL-BFM studies and diagnosed before the age of 16 between 1986 
and 2007. Of 2679 patients that could theoretically be included, attempts were made to 
contact 2303 of them (Table 1). The NHL-BFM Study Center does not record addresses 
of patients, so that 2061 were contacted via the GCCR, with the remainder of partici-
pants contacted via the last treating hospitals coordinated by the NHL-BFM Study Cen-
ter. In total, 2061 were contacted with 2574 letters via the GCCR (Table 1 and figure 1, 
Step 3a). 
Patients and families were contacted in three large and two smaller efforts: 
Table 2:  Contact via GCCR 






Since many letters were returned to the GCCR as undeliverable, 442 addresses were 
then investigated with the help of the registration offices nationwide. This explains the 
multiple primary contact waves. 
 
2.5.1 Reminder letters via GCCR 
 
1449 patients/families were contacted a second time with 1699 reminder letters (figure 
1, Step 4). Reminder letters did not contain the complete study material, but a document 
which allowed the patient/family to request the complete study material, ask for tele-






These reminder letters were sent out in three increments (Table 3): 
Table 3:  Second Contact via GCCR 





2.6   Sending out questionnaires via study center / hospitals 
 
The NHL-BFM Study Center contacted (former) patients/families who refused to give 
personal data to the GCCR or declined contact by the GCCR for any reason. Further-
more, there were other (former) patients, known to the GCCR as problematic cases, so 
for these patients it was decided that the NHL-BFM Study Center would be their initial 
contact. 
The NHL-BFM Study Center does not record addresses of (former) patients. Therefore, 
the pediatric oncology departments of cooperating hospitals were asked to support the 
NHL-2007 study by mailing the questionnaire and study material to these select (for-
mer) patients/ families. 
In July 2008, documents for the study were sent to the following hospitals with a re-
quest to support the NHL-2007 study (figure 1, Step 3b): 
Tübingen, Freiburg, Berlin-Buch, Köln-Uni, Köln Städtisches Klinikum, Münster,  
Bremen, Homburg/Saar, Aachen, Dresden, Jena, Essen, Augsburg, Hannover, Dort-
mund, Bayreuth, Nürnberg,  Kiel, Düsseldorf, Minden, Chemnitz, Datteln, Oldenburg, 
Berlin, Frankfurt, Saarbrücken, Mainz, Hamburg, Göttingen, Heidelberg, Nürnberg, 
Nürnberg Städtisches, Stuttgart, München Uni, München Harlachingen, Erlangen, Kas-
sel, Mannheim, Bonn, Karlsruhe, Erfurt, Coburg, Trier, Halle, Krefeld, Marburg, Cott-
bus, Würzburg, Siegen, Ulm, Greifswald, St. Augustin, Koblenz, Wuppertal, Rostock, 
Ludwigshafen, Lübeck und Wiesbaden.  
Study coordinators at these individual hospitals then decided which patient/family 






2.6.1 Reminder letters study center/hospitals 
 
Only select of patients/families, considered problematic due to various reasons (prob-
lematic cases, missing address, refusal to be contacted by the GCCR), were contacted 
by the NHL-BFM Study Center. 
When the reminder letters were due to be delivered, only 13-15 % of patients contacted 
via individual hospitals had agreed to participate in the NHL-2007 study. 
In addition, some hospitals only began mailing of primary letters to patients in Novem-
ber/December 2008. Due to the exhaustive effort required of cooperating hospitals to 
contact these former patients/families, and an estimated return rate of only 15% as our 
projected outcome to these reminders, is was decided to discontinue reminder letters for 
this group. 
  
2.7   Recontact of families with hematopoetic malignancies in relatives 
 
All families with a family member with lymphoma or leukemia apart from the index 
patient were recontacted to request additional information. 
These families were asked to forward a letter to the affected family member with the 
request to return the accurate diagnosis from their doctor and, if possible, an anonymous 
histology report to the study center. 
The recontact also asked the families to provide information on the grandparents of the 
index patient. Finally, a copy of the original questionnaire was enclosed with the request 
to fill in any potentially missing items. 
 
2.8   Statistical methods  
(Calculated and reported by the Institute of Medical Biostatistics, Epidemiology and Informatics, 
University of Mainz) 
 
 
2.8.1 Statistical plan 
Primary question: 
Is there an enrichment of cancer in relatives? 
 
Secondary questions: 
Is there an enrichment of childhood cancer (under the age of 15) in relatives? 




The following data was collected: 
 Number of patients 
 Number of parents, siblings, half-brothers and –sisters, nieces/nephews, children 
of the index patient, paternal and maternal aunts/uncles, and paternal and mater-
nal cousins. 
 Inquiry period 
 Birth year of the family members 
 Year of diagnosis (if cancer occurred in the family member) 
 Year of death (if a family member died) 
 
Categorical variables: twin, multiplets, gender, cancer, cancer type, leukemia type, lym-
phoma type, solid tumor type , immunodeficiency, death. 
 
Continuous variables: year of birth, year of incidence, age at time of death, age at time 
of survey. 
 
2.8.2 Standard Incidence Ratios (SIRS)  
 
In order to evaluate the obtained data, calculations of Standardized Incidence Ratios 
(SIRs) were used. A SIR in this study is an estimate of the occurrence of different type 
of cancer in the relatives of patients with childhood NHL relative to what might be ex-
pected for the German population. For each SIR a 95 % confidence interval (CI) was 
calculated to determine if the observed number of cancer cases is statistically signifi-
cantly different from the expected number or if the difference is just a random fluctua-
tion. 
The use of Standardized Incidence Ratios (SIRs) for data analyses allowed to comprise 
the time at risk of each individual mentioned in the study. 
The calendar year and age of persons (in 5-year intervals) at time of the study are 
linked, which means that predicted number of cancer cases was calculated from person-
years in 5-year spans of age. 
SIRs were calculated for the relatives of all reported cases and compared to the expected 
number of cases using incidence data from the “Saarland Cancer Registry” founded in 
1967. Data have been incomplete at the beginning of the Saarland Cancer Registry, so 
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that for relatives born before 1970, 1970-1975 incidence data was used to calculate their 
expected contribution to the observed cancer cases until their lifespan reached 1975.  
This calculation was repeated for each person only until their 15
th
 birthday. For this 
analysis, calculation of SIRs utilized incidence data from the German Childhood Cancer 
Registry using the 1980-1985 data for all earlier times.  
SIRs were calculated for any cancer, leukemia, lymphoma and Hodgkin’s disease, as 
well as for Non-Hodgkin lymphomas. SIRs for CNS, testicular cancer and pancreatic 
cancer were also calculated, as family histories of these cancers have been associated 
with childhood NHL in the literature previously.
21,19
  
95% confidence intervals were calculated assuming the Poisson distribution. (Breslow 
and Day 1987) 
Person years at the beginning of registries were not censored to avoid any bias this cen-
soring might have on estimation of SIRs. 
To ensure a conservative estimate of SIRs, all individuals reported in questionnaires (in 
spite of missing data) were used for analysis. Missing data were imputed to give the 
most conservative estimate. 
Consequently, estimated SIRs may be slightly lower than true SIRs. Missing birth-years 
were imputed using the index case’s birth-year and adding the mean distance (birth-year 
index case – birth-year relative) for each type of relative. Gender was imputed using a 
random binomial number with the probability of male sex in the overall sample. Miss-
ing information regarding death status was considered as alive. Missing information 
regarding occurrence of cancer was considered as “no cancer” except in a sensitivity 
analysis, where it was assumed that 5% of the cases with missing cancer status infor-
mation, had been diagnosed with cancer.  
In sensitivity analyses, cancer cases occurring in persons with a reported immune defi-
ciency problem were excluded. In a further analysis, index cases of Turkish descent 
were also excluded. The German Childhood Cancer Registry uses a method to identify 












3.1 Results of the Pilot Study 
 
In total 98 questionnaires were sent out for the pilot study. Sixty of 98 sent question-
naires were completed and returned to the study center, for a return rate of 62 %. Our 
rate of return of 62 % and 84-86 % of items completed per person, fulfilled both goals 
established for the pilot study.   
 
 
Figure 2a – Analyzability of 1074 subjects reported on 60 questionnaires (Pilot Study) 
 
Returned questionnaires contained information on 1074 family members (p=1074) of 
(former) pediatric oncology patients. 856 persons of p were completely analyzable and 
with no missing items, equating to ~ 80 % (79,7 %) of p (Figures 2a,b). Analyses re-
vealed similar mistakes on several questionnaires, and these incomplete items led to a 
loss of 13 % (135 persons) of evaluable family members due to missing information on 
the status if these persons were still alive. Information about birth year was incomplete 
for another 44 persons (4 %). In 13 persons (1%), both year of birth and whether they 
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were still alive was incomplete. Information regarding if a person ever was diagnosed 
with cancer was incomplete for 12 persons (1%). In six persons, information about 
whether they had ever been diagnosed with cancer and if they were still alive were in-
complete. In seven persons (1%) information about birth year and if they ever had can-
cer was incomplete. In one person information about the year of diagnosis of cancer was 
incomplete. In total, for 192 persons only one statement was left incomplete. 
Information was blank for the question: ‘Dead/alive’ in135/1074 persons, ‘year of birth’ 
in 44/1074 persons, ‘cancer yes/no’ in 12/1074 persons and ‘year of diagnosis’ in 
1/1074 person. This equates to a completion of 84 % in cousins and 86 % in the remain-
ing family members. 
 
 












Analyzability of persons 
n=1074 
 (60 questionnaires ~rate of return 62%) 
Complete 856 Dead or alive: 135
Year of Birth: 44 Dead/Alive + Year of Birth: 13
Dead/Alive + Cancer: 6 Cancer: 12
Year of Birth + Cancer: 7 Year of Diagnosis: 1
s 
Number of persons who couldn't be completely analyzed, because of 
missing information on following topics: 
 
 24 
3.1.1 Discussion of pilot questionnaire results 
 
With a return rate of 62 % the goal of 60 % return rate was achieved. 
856 of 1074 persons were completely analyzable, which equates to a 79,7 % rate. For 
each family member, six items –for cousins seven items- required responses. 
For 192 persons, only one statement was left incomplete. This represents an 84% rate of 
analyzable items for cousins, and 86% for all other family members. 
Overall we obtained 100 % of analyzable data for 856 persons, and an additional 192 
persons yielded 84% - 86% analyzable items. 
This equates to analyzable data of over 80% for 1048 persons, which is approximately 
97 % of the entire cohort.  
The goal to achieve >80% analyzable data per person was likewise achieved. 
21% of persons were incompletely analyzable. The major source of error, accounting 
for 13 % of persons with one or more incomplete items, was the question concerning 
whether the family member was still alive or had died. 
Furthermore we observed that six of the 60 questionnaires accounted for a dispropor-
tionately high percentage of the entire error ratio. With regard to content, these six ques-
tionnaires were not useful for the actual study.  
These six questionnaires were solely responsible for 18,5 % of incomplete answers re-
garding the question dead/alive, for 11,4 % of incomplete items for the year of birth and 
for 85 % of persons with incomplete information for the year of birth and ‘cancer 
yes/no.’ 
Had these six questionnaires been omitted from analysis, 82 % of persons were com-
pletely analyzable and the major flaw of the questionnaire, the question concerning 
whether persons are still alive/died, would have represented 11 %. 
Therefore, a small part of the questionnaire accounted for majority of the error ratio, 
which thus indicates the principal weakness of the pilot questionnaire. 
  
Following telephone interviews, it was apparent, that the question regarding whether 
family members were still alive was merely overlooked in many cases. 
There were different reasons for incomplete responses to missing birth years. Respond-
ents often didn’t know this information; in other cases, they felt, these dates were not 
important and opted to leave them out. It is challenging to categorize these individual 
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explanations statistically, but they definitely reveal a problem in the questionnaire’s 
design, which was the exact purpose of the pilot study. 
Of importance, not all persons who completed a questionnaire were contacted. There-
fore, these answers reflect only a minority of the participants and may not be representa-
tive of the entire cohort. Part of the respondent population is of foreign ancestry, so lan-
guage barriers present a potential problem for a written questionnaire.  However, this 
possibility cannot be objectively verified or falsified. 
Because the questionnaire contained too few rows for responses, especially as pertains 
to cousins, aggravated participants, who had to create an additional sheet and add it to 
the questionnaire. Accordingly, additional sheets must to be looked at critically, since 
the respondent might be more likely to not mention all family members or might make 
other mistakes when drafting a self-created chart. 
This unintended additional workload for the respondent might therefore be a potential 
further source of inaccurate responses.  
In total, the pilot study was assessed to be a success. All clarified goals were achieved, 
and important weaknesses of the questionnaire were disclosed, which subsequently led 










3.2 Results of the Study NHL-2007 
 
3.2.1 Return rate 
 
Families were contacted starting in June 2008, the last questionnaire was returned to the 
GCCR or NHL-BFM study center in February 2009.  
2303 persons were attempted to contact. 2198 of these 2303 persons were definitely 
contacted (Figure3). Responses from 1004 families were received, which equals a re-
sponse rate of 43.6%. In eight families the patient in question was an adopted child. 14 
families replied, that cancer had never occurred in the family. Two questionnaires were 
excluded for double reporting in sib-pairs (one male/male, one female/female), and the 
double reported relatives in a cousin-pair were also excluded, leaving 979 question-









36 families with another hematopoietic malignancy were re-contacted and asked for 
detailed information. 15 of these re-contacted families sent back grandparental infor-
mation. 7 families also returned histological data; 5 families provided information on 
missing items of their original questionnaire. 
Table 4:  Responder/Non-Responder 
Included 2303 
Definitely contacted 2198 
Responder 1004 
Non-Responder 1299  
 
Characteristics, such as age at diagnosis or sex of the index cases compared to non-
responders are listed in table 5 (families with an adopted index case child or reporting 
no cancer in the family are not shown). Mean age at diagnosis was 9.1 years (if counted 
in integers, for example‚’4 years’ instead of 4.4 years, the mean age at diagnosis would 
be 8.6). Males represented 71% of cases. Deceased cases and cases of Turkish descent 
participated less frequently than cases where the index case was still alive or of non-
Turkish descent. Parents of very young children at diagnosis (under 2 years) refused 
participation more often (<30%). The distribution of different NHL diagnoses was simi-
lar between responders and non-responders. Willingness to participate decreased with 
increasing temporal distance to the diagnosis, from 57% in more recent patients to 32% 
for patients diagnosed prior to 1990. In 13% of contacted families, the patient had died; 
in these families willingness to participate was only 27%. For a subset of cases a Turk-
ish ethnic background was already known from a previous GCCR study.
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 In the NHL-
2007 study 5.6 % of families had a Turkish background as assumed by an algorithm 
used on the names. Of these families, only 16% participated (likely due to difficulties 
understanding the questionnaire). Further details on participating families and non-
responders are listed in table 5. 
Baseline characteristics of non-responders are from data from the GCCR and the NHL-







3.2.2 Evaluable Cases 
 
Families of adopted children (where index patient was adopted) and relatives with im-
possible birthdates (n=2) were excluded from analysis. One reported ”sibling” with can-
cer was excluded because he was born in the same year as the index case (and given the 
same first name) which was impossible given the index case’s birth date in May. We 
also excluded a reported “child” of the index case who was listed as having been born in 
the same year as the index case. Presumably, in each of these two cases parents filled 
out the questionnaire and were confused with the family relations.  
Three NHLs were double reports, as mentioned above. In these families, one randomly 
chosen questionnaire from the sib pair and one questionnaire from the double-reported 
relatives of the cousin-cousin pair were excluded. 
In a sensitivity analysis, four cancer cases also reporting an immune deficiency syn-
drome were excluded (One NHL (XLP syndrome), two leukemia cases and one Hodg-
kin’s disease). 
For 14 families who reported, that there were no further cancer cases in their family 
without providing detailed family structure information, a hypothetical family using the 
mean number of relatives of each type of relative was imputed to those cases, account-
ing for a total of 13 family members each. 




Table 5: Details of participating index cases compared to data from non-responders. Families of adopted index cases 
(n=8) or those reporting no cancer case without completing the questionnaire (n=14) were excluded from this analy-
sis. 





N        1004          1299  














































Other specific NHL 
B-NHL (nfc) 




























 83 (8.5%) 213 (16.4%)  
(T-LBL= T-cell lymphoblastic lymphoma, B-LBL= B-cell lymphoblastic lymphoma; B-
ALL=B-cell acute lymphoblastic leukemia, PMBL= Primary mediastinal B-cell lymphoma, 






Table 6: Number of reported relatives of 979evaluable index NHL patients 





12630 12.9 11 2-76 33 (0-87) 
N=10071 
Parents  1953  2 2 2-2 48  (22-79) 
N=1709 




220 0.2 0 0-10 4 (0-36) 
N=195) 












1772 1.8 1 0-13 49 (0-88) 
Maternal 
Cousins 




2558 2.6 2 0-37 21 (0-60) 
N=1877 
 
3.2.3 Reported cancer cases in Relatives of all ages 
 
In total 306 family members with any kind of cancer were reported from 12630 rela-
tives (table 7). When comparing total cancer cases in relatives observed to the number 
of expected, there were actually fewer cases seen than expected. 
A slight rise in SIR of leukemia and lymphoma was observed (48 observed versus 39.2 
expected cases; SIR 1.22, 95 % CI 0.9-1.62). When considering leukemias and Hodgkin 
lymphomas only, slightly higher rates were also seen (33 compared to 26.2 expected 
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cases; SIR 1.26 95 % CI 0.87-1.77). No significant clustering of NHL was seen (SIR 
1.14, 95% CI 0.64-1.87). 
Since Rudant et al
 21
 reported higher SIRs for testicular and pancreatic cancers in rela-
tives of children with NHL, SIRs for these entities were also calculated. The NHL-2007 
study did not confirm this finding for testicular cancer, but did show an increased inci-
dence of pancreatic cancer.  
 
Table 7: Expected and observed cases in 1-3 degree relatives of childhood NHL cases 
 Expected # of 
cases 
Observed # of 
cases 
SIR 95% CI 
Total cancers 363.3 306 0.84 0.75-0.94 
Leukemias and 
lymphoma 




26.2 33 1.26 0.87-1.77 
NHL 13.2 15 1.14 0.64-1.87 
Testicular can-
cer 
15.7 16 1.02 0.58-1.66 
Pancreatic can-
cer 
4.4 8 1.82 0.78-3.58 




15.6 25 1.60 1.04-2.37 
 
 
Table 7a: Expected and observed cases and SIRs after removal of relatives of cases with known immunodeficiency 
 Expected # of 
cases 
Observed # of 
cases 
SIR 95% CI 
Total cancers  363.3 302 0.83 0.74-0.93 
Leukemia and 
lymphoma 




26.2 30 1.15 0.77-1.64 
NHL 13.2 14 1.06 0.58-1.78 
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Table 8: Expected and observed cases and SIRs in relatives under 15 years of age 
 Expected # of 
cases 
Observed # of 
cases 
SIR 95% CI 
Total Cancers in 
relatives  <15 












8.5 8 0.94 0.41-1.86 
NHL in relatives 
<15 
1.3 6 4.50 1.65-9.80 
CNS in relatives 
<15 
2.7 10 3.75 1.80-6.90 
 
Table 8a:  Expected and observed cases and SIRs in relatives below the age of 15 without cases with known immu-
nodeficiency 
 Expected num-




SIR 95% confidence 
interval 
Total Cancers in 
relatives  <15 









8.5 7 0.82 0.33-1.70 
NHL in relatives 
<15 






3.2.4 Cancers reported in relatives below the age of 15 at diagnosis 
 
However, the outcome was quite different, if only age 0-14 relatives are considered. 
Strikingly, many NHL cases in relatives occurred at a very early age. The SIR for NHL 
up to age of 14 was marked increased (4.50 95% CI 1.65-9.80). Excluding the case with 
known XLP (as a known heritable cause) SIR remained high (3.75, 95% CI: 1.22-8.75). 
The increased SIRs observed in this age group for total cancer overall and leukemia and 
lymphoma derived from the high number of NHL cases. SIRs were calculated, after 
removal of cases with reported immune deficiency syndrome or XLP. Numbers are giv-
en in tables 7a and 8a. 
Except for the high number of NHL cases, the other diagnoses showed a typical distri-
bution of childhood cancers. (Figure 4) The female/male ratio was 1:1, and NHL sub-
types were represented in the index cases at about the same frequency as in the entire 
sample. Only a higher percentage of Turkish descent was observed compared to the rate 
in all participating families. Additional details are listed in table 9. 
 
 




Table 9: Description of overall cancer cases in relatives below 15 years of age (n=28)  






Type of tumor in relative 



















1 missing (birthyear 2002)  
















Turkish descent in index 
case 
 3/23=12% 
5 missing information 


















1       
2 (7%) 







3.2.5 Reported NHL cases 
 
Fifteen NHL cases were reported in relatives of all age groups. The mean age of diag-
nosis of NHL in relatives was 29.1 (median 33.5) years. The mean age of diagnosis for 
index cases was 9.6 (median 10), which is comparable to the entire sample (mean 9.1, 
median 9 years). Two affected sib-pairs (one male/male, one female/female), 3 
cousin/cousin pairs (2 male/male, 1 female/male, 2 maternal, 1 paternal) and two father-
son pairs, in addition to 8 affected aunts/uncles (5 paternal) were reported. 8 pairs were 
sex concordant, with 7 of these male/male. One affected male sib pair was reported to 
have XLP syndrome. No NHL subtype was clearly over-represented in index cases. A 
diagnosis of CB occured more often in index cases than in the entire sample [3/15 
(20.0%) compared to 9.5% in the overall sample], but the difference was not statistical-
ly significant. The percentage of male index cases was 80%, and slightly higher than in 
the 70.6% male predominance of the entire cohort.  
 
 
Table 10: Diagnosis in index cases of families with second NHL cases (n=15)  








other spec. NHL 
B-NHL (nfc) 
2 (13.3 %) 
0 (0%) 
3 (20%) 
2 (13.3 %) 
0 (0%)  
3 (20%) 
2 (13.3 %)   
0 (0 %) 
1 (6.7 %)       
















Table 11: Details of potential familial NHL cases (double reported pairs removed) 















Case 1 2 M M Brother Burkitt B-NHL (nfc)  
Case 2 11 F F Sister CB Burkitt  
Case 3 4 M M Paternal 
cousin 
T-LBL T-LBL  




NHL (nfc) B-NHL (nfc)  
Case 5 49 M M 
 
Father MCL ALCL (nfc)  







5 F M Paternal 
aunt 
NHL (nfc) NHL (nfc) 





Case 9 62 M M Father FL 
grade II 
Burkitt  
Case 10 Missing F M Maternal 
aunt 
NHL (nfc) CB  
Case 11 38 M F Maternal 
cousin 
NHL (nfc) Burkitt  
Case 12 47 M M Paternal 
uncle 
T-NHL CB  
Case 13 35 M M Maternal 
uncle 
ALCL t(2;5) T-LBL  
Case 14 32 F M Paternal 
aunt 
CB CB  









3.2.6 Diagrams of the 15 reported NHL cases in relatives 
 
The next section will visualize the genealogy of families with a family member with 
non-Hodgkin-lymphoma apart from the index patient. The index patient is labeled grey.  
Female family members are diagramed in squares, male family members are diagramed 
as circles:  
 
 
All maternal relatives are found to the right of the index patient, the paternal relatives to 
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4. Discussion  
 
Several studies implicate, that there might be a familial predisposition for NHL in 
childhood.
 4,16,29 
However, these studies comprised only small numbers of childhood 
NHL patients. The NHL-BFM study center has a large collection of >2500 patients and 
seems to be in a position to serve as professional basis to pursue the question of whether  
there is a familial clustering in (German) childhood NHL cases. 
2303 persons were attempted to contact, of whom 2198 were definitely contacted. Re-
sponses from 1004 families were received, which equals a response rate of 43.6 %. 
 
Response rate 
The response rate of 43.6 % was lower than excepted based on the results of the pilot 
study, which had a return rate of 62 %. Two factors could account for this discrepancy: 
A first difference could derive from the cohort. The pilot study comprised patients all 
treated at the same hospital, which then contacted them later on. 
In contrast, the NHL-2007 study was conducted nationwide, so the majority of partici-
pants were contacted by a third party, the GCCR. 
A second difference is that in the pilot study, index patients were treated for any child-




The participation rate of 43.6% is impressive when considering the time span since di-
agnosis, the complexity of patients contacted and the extent of the questionnaire re-
quired by the NHL-2007 study. Cummings et al (2001)
 
reported, that the average re-
sponse rate for mailed surveys containing over 1000 observations is approximately 
52%.
6 
Our analysis of non-responders showed a similar distribution of specific NHL 
diagnoses in responders and non-responders (Table 5). Rather, likelihood of participa-
tion decreased with increasing temporal distance from the diagnosis, from 57% in recent 
patients to 32% in patients diagnosed prior to 1990. 
 
Families of deceased cases and cases of Turkish descent participated less frequently 
than families where the index case was still alive or of non-Turkish descent. Parents of 
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children who were very young at diagnosis (<2 years) refused participation more often 
(<30% participation). In 13% of contacted families, the index patient had died before 
this study; perhaps not surprisingly, in these families participation was only 27%. A 
subset of cases was known to be of Turkish descent from a previous GCCR study. In the 
NHL-2007 study 5.6% of families were Turkish. Of these families, only 16% participat-
ed. This low response rate likely relates to difficulty understanding the lengthy ques-
tionnaire. This same problem was noted in the pilot study. During the pilot study’s tele-
phone interviews, language problems were frequently encountered with Turkish fami-
lies, although this was not quantified. 
  
Questionnaires reported information 
979 questionnaires reporting data pertaining to 12630 family members were used for 
analysis. 36 families with at least one hematopoietic malignancy in relatives were re-
contacted for additional detailed information.  
The nature of a mailed survey is that data is self-reported, so these data cannot be con-
firmed. Hence, there is a possible under – or over-reporting bias.  
In total, 306 of 12630 relatives had a cancer diagnosis, which is slightly less than ex-
pected [SIR of 0.84 (0.75-94)]. These data give the impression, that there was no over-
reporting in the NHL-2007 study. 
It would rather seem as if there might have been under-reporting. If 5% of persons re-
ported as “don’t know if they have/had cancer” and 5% of those with missing cancer 
information (n=179+262=441) actually had been diagnosed with cancer, 22 additional 
cases would have been tabulated, giving an SIR of 0.90 (0.81-1.01). 
 
Slightly elevated SIRs for leukemia and lymphoma were observed (SIR 1.22, 95% CI 
0.9-1.62) and considering leukemia and Hodgkin lymphoma only (SIR 1.26, 95% CI 
0.87-1.77). No general clustering for NHL was seen (SIR=1.14 0.64-1.87), and there 
were no excess malignancies in the entire cohort. 
 
However, an analysis considering exclusively cancer in relatives diagnosed before the 
age of 15 showed a very high SIR for NHL (4.5, 95% CI 1.65-9.80) and CNS tumors 
(SIR 3.75, 95% CI 1.80-6.90). This result remained significant even after excluding the 
one case with known XLP immune deficiency (SIR 3.75 95%, CI 1.22-8.75). 
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Both a history of childhood NHL and CNS tumors <15 years of age showed a statisti-
cally significant association with childhood NHL.  
This clustering is a very important finding and supports the idea of a familial predispo-
sition for NHL in childhood -which not only arose in the NHL-BFM study center after 





Rudant et al (2007)
 21
 found a significant link between childhood NHL and pancreatic 
cancer (SIR 1.82, 95% CI 0.78-3.58). Our study confirmed that observation, but Rudant 
et al also reported an association of childhood NHL and testicular cancer, which our 
data do not support (SIR 1.02, 95 % CI 0.58-1.66).  
 
One of the goals of the NHL-2007 study was to identify high risk groups and discern 
whether there are different cancer risks for different NHL subtypes.  
Due to the relatively small number of cases in the NHL-2007 study it was not possible 
to obtain a definitive conclusion on this question. In our cohort, no clustering was seen.  
Since NHL is an extreme heterogeneous group of lymphoid malignancies a larger co-
hort would be needed to have representative numbers for the different subtypes. 
 
Nonetheless, our data give a profound basis for more calculations than we have done by 
now. Some studies for example calculated relative risks for different family members.
 
4,27,28   
Calculations whether enrichments of overall cancer/lymphoma/leukemia/solid tumor 
rates occur in siblings, parents, nieces/nephews, aunts/uncles and cousins of index cas-
es, respectively are already planned. 
 
Choice of Cancer Registries 
Our choice of cancer incidence rates for comparison also merits consideration. Germany 
does not have a family-cancer registry, so that conditions are not comparable to condi-
tions in Sweden
 
for example, which has a nation-wide family-cancer database, including 
all Swedes since 1932.
9
 The Saarland cancer registry was founded in 1967. For the 
NHL-2007 study, data beginning in 1975 from the Saarland registry was used for calcu-
lating the SIRs as well as data from the GCCR. There are no other representative Ger-
man registries that could have been used instead.  
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5.   Summary 
 
In Germany, NHL are the third most common cancer in children. Although significant 
progress has been made in the treatment of childhood NHL, the majority of etiological 
factors of NHL and its subtypes remain unclear. The NHL-2007 study aimed to deter-
mine if there is an excess of malignancies, especially lymphoid malignancies in rela-
tives of childhood NHL patients for the entire group, as well as for distinct biological 
subgroups of childhood NHL. 
In the NHL-2007 study included participants were former patients with NHL in child-
hood (ages 0-15) who were treated in cooperative, multicenter study groups between 
1986 and 2007 in Germany.  
To retrieve data from families of former patients with childhood NHL, a special ques-
tionnaire was developed and tested in a pilot study including 98 families with a child 
who had a cancer diagnosis between 1981 and 2006.  The pilot study, containing infor-
mation on 1074 family members disclosed weaknesses of the questionnaire, which sub-
sequently led to improvements in the finalized questionnaire used for the NHL-2007 
study. 
In the following a database was developed in cooperation with the GCCR.  This data-
base included all necessary data from the NHL-BFM and GCCR data bases, as well as 
all data from the questionnaire.  
After the implementation of the basic prerequisites the logistical requirements where 
fathomed. The majority of participants were contacted via the GCCR. A smaller, select-
ed part was contacted by the NHL-BFM study center via cooperating hospitals nation-
wide. 
In the NHL-2007 study 2303 persons were attempted to contact, of whom 2198 were 
definitely contacted. 1449 patients/families who didn’t reply after the first contact, were 
contacted a second time with 1699 reminder letters. 
Responses from 1004 families were received, from which 979 questionnaires reporting 
data pertaining to 12630 family members were used for analysis. 36 families with a sec-




The observed numbers of cancer cases have been compared to the expected ones giving 
standardized incidence ratios. The expected numbers were calculated using the cancer 
registry of the Saarland and the data from the German Childhood cancer registry. 
In total, 306 of 12630 relatives had a cancer diagnosis, which is slightly less than ex-
pected (SIR 0.84 95% CI 0.75-94). Slightly elevated SIRs for leukemia and lymphoma 
were observed (SIR 1.22, 95% CI 0.9-1.62) and considering leukemia and Hodgkin 
lymphoma only (SIR 1.26, 95% CI 0.87-1.77). No general clustering for NHL was seen 
(SIR=1.14 0.64-1.87), and there were no excess malignancies in the entire cohort. 
However, an enrichment of childhood NHL and childhood CNS tumors were reported. 
Both a history of childhood NHL (< 15 years old) (SIR 3.75 95%, CI 1.22-8.75) and 
CNS tumors <15 years of age (SIR 3.75, 95% CI 1.80-6.90) showed a statistically sig-
nificant association with childhood NHL. 
Our data did also show an increased incidence of pancreatic cancer (SIR 1.82, 95% CI 
0.78-3.58).   
One of the goals of the NHL-2007 study was to identify high risk groups and discern 
whether there are different cancer risks for different NHL subtypes.  
Due to the relatively small number of cases in the NHL-2007 study it was not possible 
to obtain a definitive conclusion on the NHL subgroup question. In our small cohort, no 
clustering was seen. Based on our results, we recommend further studies encompassing 
a greater number of subjects to evaluate whether different NHL subtypes show individ-
ual risk associations. For Germany, we could only recommend collecting data over 
time, since our cohort already comprised all possible subjects up to age 15 with child-
hood NHL registered nationwide since 1986. Another possibility may be to design a 
meta-analysis, to evaluate individual risk associations for different NHL subtypes. 
  
Last but not least, it should also be noted that the collected data from the NHL-2007 
study has potential utility in further evaluations. We plan, for example, to calculate rela-
tive risks for different kind of cancers for the first to third degree family members of 
NHL childhood patients, respectively.  
Besides a wide range of calculations that can be done with the reported data, the NHL-
2007 study has a database pertaining data to 12630 relatives. It can be used to identify 
subjects with specific characteristics for further studies, p.e. the NHL-2007 study identi-
fied 36 families with a second hematopoietic malignancy, who could as a cohort be a 
valid basis for a more profound study. 
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We could confirm a significant enrichment of childhood NHL and childhood CNS tu-
mors. Data pertaining to 12630 relatives have been collected and will build a profound 































Non-Hodgkin-Lymphome (NHL) sind in Deutschland die dritthäufigste maligne Er-
krankung im Kindesalter. Während die Medizin einen bedeutenden Fortschritt bei der 
Behandlung von NHL im Kindesalter verzeichnet, sind nur wenig Forschungs-
ergebnisse mit Bezug auf die Ätiologie des NHL und seinen Subtypen bekannt. 
In die NHL-2007 Studie wurden  alle (ehemaligen) Patienten eingeschlossen, die an 
NHL im Kindesalter erkrankt waren (Altersspanne 0-15) und in den multizentrischen 
Behandlungsstudien von 1986 bis 2007 in Deutschland behandelt worden sind. 
Für die NHL-2007 Studie wurde ein eigens angefertigter Fragebogen entwickelt und in 
einer Pilotstudie getestet. Entsprechend der Ergebnisse der Pilotstudie wurde der Frage-
bogen für die NHL-2007 Studie optimiert und eine passende Datenbank programmiert. 
  
Es wurde für 2303 Personen ein Kontaktversuch gestartet, von denen 2198 tatsächlich 
kontaktiert werden konnten. Von den 1004 Personen die geantwortet haben, konnten 
979 Fragebögen ausgewertet werden. Es wurden Informationen zu 12630 Familienmit-
gliedern dokumentiert und analysiert. Es kristallisierten sich 36 Familien heraus, in de-
nen eine weitere Person an einer hämatologischen Krebserkrankung erkrankt war. Diese 
Familien wurden noch einmal kontaktiert um detaillierte Informationen bzgl. dieses 
Familienmitglieds zu erhalten. 
Es wurden Standard Incidence Ratios  (SIRs) berechnet um erwartete und tatsächlich 
aufgetretene Anzahl von Krebserkrankungen zu vergleichen.  
Insgesamt wurde bei 306 von 12630 Familienmitgliedern eine Krebsdiagnose dokumen-
tiert, was etwas geringer ist als in der berechneten Vergleichsgruppe. Es fanden sich 
leicht erhöhte SIRs für Leukämien und Lymphome sowie für Leukämien und Hodgkin-
Lymphome. Es trat keine Häufung von Non-Hodgkin-Lymphomen auf. 
 
Es zeigte sich allerdings eine Häufung von NHL und ZNS-Tumoren im Kindesalter: 
Sowohl NHL im Kindesalter (<15 Jahre) (SIR 3.75 95%, CI 1.22-8.75) als auch ZNS-
Tumoren im Kindesalter (<15 Jahre) (SIR 3.75, 95% CI 1.80-6.90) zeigten eine statis-
tisch signifikante Assoziation zu NHL-Erkrankungen im Kindesalter. 
 
Unsere Daten zeigten zusätzlich ein erhöhtes Auftreten von Pankreastumoren.  
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Ein Ziel der NHL-2007 Studie war es Hochrisikogruppen zu identifizieren und heraus 
zu arbeiten, ob es verschiedene Risikoprofile für verschiedene NHL-Subtypen gibt. 
Aufgrund der insgesamt geringen Anzahl von Krebserkrankungen in der NHL-2007 
Studie und gleichmäßigen Verteilung von Subtypen war es nicht möglich dieser Frage 
auf den Grund zu gehen. In unserer Kohorte wurde keine spezifische Häufung verzeich-
net. 
Aufgrund unserer Ergebnisse empfehlen wir zur Klärung der individuellen Risikoprofile 
verschiedener NHL-Subtypen das Auflegen einer Studie mit größerer Teilnehmerzahl. 
Für Deutschland ist dies aktuell nicht möglich, da unsere Studie bereits alle zwischen 
1986 und 2007 an NHL im Kindesalter erkrankten Menschen enthielt. Hier könnten 
höchstens Patientenkohorten über einen noch längeren Zeitraum beobachtet werden. 
Eine andere Möglichkeit wäre das Erstellen eine Meta-Analyse aus Daten verschiedener 
Länder. 
Schlussendlich bleibt fest zu halten, dass die gesammelten Daten der NHL-2007 Studie  
mit Informationen über 12630 Menschen viele Möglichkeiten zu weiteren Daten-
analysen geben. Es ist beispielsweise konkret geplant, das relative Risiko für Verwandte 
verschiedenen Grades für verschiedene Krebsarten zu berechnen. 
Neben diesen und ähnlichen Analysen ist es auch möglich aus den vorliegenden Daten 
Menschen mit spezifischen Erkrankungsmerkmalen zu identifizieren, um weitere Stu-
dien durchzuführen. Bestes Beispiel für solch eine Kohorte wären beispielsweise die 36 
Familien, in denen eine weitere maligne hämatologische Erkrankung diagnostiziert 
worden ist. 
 
Insgesamt konnten wir mit der Studie NHL-2007 eine signifikante Häufung von NHL 
und ZNS-Tumoren im Kindesalter bestätigen und haben mit der Datensammlung von 
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Studie zur Familiären Prädisposition für Non-Hodgkin-





Ich habe die Patienteninformation über die Ziele und Vorgehensweise der 
Familienbefragung gelesen und verstanden. 
Ich erteile hiermit mein Einverständnis zur Teilnahme an dieser Befragung und zur 
Verwendung der auf dem Fragebogen angegebenen Daten zur wissenschaftlichen 
Auswertung. Studienspezifische Daten oder Daten, die Inhalt dieser Studie sind, 
werden in Gießen (NHL-BFM Studienzentrale am Zentrum für Kinder- und 
Jugendmedizin, Abt. Päd. Hämatologie und Onkologie der Justus Liebig-Universität) für 
die Dauer der Studie gespeichert. Sie werden zu Auswertungszwecken anonym an die 
Abteilung Biometrie des IMBEI (Institut für Medizinische Biometrie, Epidemiologie und 
Informatik der Universitätsklinik Mainz) weitergeleitet. Die Auswertungen erfolgen unter 
voller Wahrung der ärztlichen Schweigepflicht und des Datenschutzes. Nach Abschluss 
der Studie werden die pseudonymisierten Daten am DKKR archiviert. 
Die im Fragebogen abgefragten Nummern / Vornamen der Verwandten dienen nur der 
eindeutigen Zuordnung des Verwandtschaftsverhältnisses und werden nicht als 
Namen, sondern nur als Nummerncode gespeichert.  
Ich habe verstanden, dass ich eventuell zu den von mir gemachten Angaben noch 
einmal kontaktiert werden kann. 
Das Einverständnis zur Studienteilnahme und Datenverarbeitung ist freiwillig und kann 
von mir jederzeit ohne Angabe von Gründen widerrufen werden. Durch die 










Unterschrift des Patienten bzw.                   Ort, Datum 
des/der Sorgeberechtigten                    
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Fragebogen 




Patientennummer:  I__I__I__I__|   Geburtstag: I__I__I |__I__| |__I__I__I__| 
 
 
Fragen zu dem an Lymphom erkrankten Kind/Jugendlichen 
 
 
Geschlecht:  weiblich  männlich 
 
Ist bei dem Kind/Jugendlichen eine Immunschwäche bekannt?     nein  ja    
Wenn ja, welche? _________________________________ 
Ist das Kind Mehrling? nein  ja    
 
(nur falls oben “ja” angekreuzt:) 
Zwilling   nein  ja      eineiig  zweieiig 
Drilling    nein  ja    
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m / w 
Krebs 






Vater  M    
Mutter  W    
 
Nur falls sie bei Krebs „ja“ angegeben haben:  
 Genaue Diagnose 
Vater   
Mutter  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
 
Ist ein Elternteil des Patienten verstorben? 
 nein  ja   , und zwar Mutter     Vater          beide   
 



















1       
2       
3       
4       
5       
6       
7       
8       
 
Nur falls sie bei Krebs „ja“ angegeben haben:  
 
Nr. & Vorname Genaue Diagnose 
  
  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
Ist eines oder mehrere der Geschwister Halbgeschwister? 
 nein  ja   , und zwar (Vornamen/Nr.). ...............................................................  
                            Gemeinsames Elternteil:  Vater       Mutter 
 
Ist eines der Geschwister des Patienten verstorben? 
 nein  ja   , und zwar (Vorname/Nr)………….. 
 
 Todesjahr: I__|__I__I__I 
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3. Nichten und Neffen des an Lymphom erkrankten Kindes (Patient): Anzahl:  I__I__I 























Nein / Ja, 
welche? 
1        
2        
3        
4        
5        
6        
7        
 
Nur falls sie bei Krebs „ja“ angegeben haben.  
 
Nr. & Vorname Genaue Diagnose 
  
  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
 
Ist ein(e) Nichte / Neffe verstorben? 
 nein  ja   , und zwar (Vorname/Nr)…………………………………….. 
 


















Nein/ Ja, welche? 
1       
2       
3       
4       
 
Nur falls sie bei Krebs „ja“ angegeben haben: 
 
Nr. & Vorname Genaue Diagnose 
  
  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
 
Ist eines der Kinder des Patienten verstorben? 
 nein  ja   , und zwar (Vorname/Nr)…… ………….. 
 
 Todesjahr: I__|__I__I__I  
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Fragen zu 
Tanten/Onkel des an Lymphom erkrankten Kindes mütterlicherseits: 
 
 
5. Leibliche Geschwister der Mutter des an Lymphom erkrankten Kindes:      Anzahl: I__I__I 













schwäche Nein/ Ja, 
welche? 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
 
 
Nur falls sie bei Krebs „ja“ angegeben haben: 
 
Nr. & Vorname Genaue Diagnose 
  
  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
 
Ist ein(e) Tante / Onkel des Patienten mütterlicherseits verstorben? 
 nein  ja   , und zwar (Vorname/Nr)………………………………………………. 
. 
  Todesjahr (Tante/Onkel Nr.|__|): I__|__I__I__I  
 Todesjahr (Tante/Onkel Nr.|__|): I__|__I__I__I 
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Fragen zu 
Tanten/Onkel des an Lymphom erkrankten Kindes väterlicherseits: 
 
 
6. Leibliche Geschwister des Vaters: Anzahl:    I__I__I 













schwäche Nein / Ja, 
welche? 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
 
Nur falls sie bei Krebs „ja“ angegeben haben:  
 
Nr. & Vorname Genaue Diagnose 
  
  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
 
Ist ein(e) Tante / Onkel väterlicherseits verstorben? 
 nein  ja   , und zwar (Vorname/Nr)……………………………………………….. 
  
 Todesjahr (Tante/Onkel Nr.|__|): I__|__I__I__I 
 Todesjahr (Tante/Onkel Nr.|__|): I__|__I__I__I 
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Vielen Dank, dass Sie soweit schon alles ausgefüllt haben. Wir wissen, dass es etwas 
schwierig sein könnte alle Daten zu den leiblichen Cousins und Cousinen des an 
Lymphom erkrankten Kindes zu bekommen. Für uns sind diese Daten aber sehr 
wichtig! Wir wären Ihnen sehr dankbar, wenn Sie es trotzdem versuchen würden.  
 
 
7. Leibliche Cousins / Cousinen des an Lymphom erkrankten Kindes (Patient)       





















Nein / Ja, 
welche? 
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
 
Nur falls sie bei Krebs „ja“ angegeben haben: 
 




Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte 
Anhang Seite 9 aus. 
 
Ist ein(e) Cousin / Cousine des Patienten mütterlicherseits verstorben? 
 nein  ja   , und zwar (Vorname/Nr)……………………………………………….. 
  
 Todesjahr (Cousin(e) Nr.|__|): I__|__I__I__I 




Danke, dass Sie sich die Mühe gemacht haben. Es ist wichtig für uns zu wissen, ob die 




Angaben zu diesen Cousins/Cousinen sind vollständig?  nein   ja     
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8. Leibliche Cousins / Cousinen des an Lymphom erkrankten Kindes (Patient) 





















Nein / Ja, 
welche? 
1        
2        
3        
4        
5        
6        
7        
8        
9        
10        
11        
12        
13        
14        
15        
 
Nur falls sie bei Krebs „ja“ angegeben haben: 
 




Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
 
Ist ein(e) Cousin / Cousine des Patienten väterlicherseits verstorben? 
 nein  ja   , und zwar (Vorname/Nr)……………………………………………….. 
  
 Todesjahr (Cousin(e) Nr.|__|): I__|__I__I__I 




Danke, dass Sie sich die Mühe gemacht haben. Es ist wichtig für uns zu wissen, ob die 








Bitte weiter auf Seite 9 
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ANHANG 
 
Sie haben angegeben, dass einer oder mehrere Ihrer Verwandten an einer 
Leukämie (Blutkrebs), Lymphom (Lymphdrüsenkrebs) erkrankt ist/war? 
  
Wir möchten Sie bitten für jede Personen zu der Sie angegeben haben, dass sie an 
einer der oben genannten Krankheiten erkrankt waren (sind) jeweils eine eigene Seite 
(Seite 9,10 und 11 sind identisch) auszufüllen und möglichst genaue Angaben zu 
machen: 
 
Verwandtschaftsverhältnis (z.B. Tante mütterlicherseits):______________________ 
 
Vorname und Nr : _______________________ 
  
Kreuzen Sie bitte das Zutreffende an: 
 
 Leukämie (Blutkrebs)  
 
Wenn ja:    
 
Akute lymphatische Leukämie (ALL)      
Chronisch lymphatische Leukämie (CLL)  
 
Akute myeloische Leukämie (AML)    
Chronische myeloische Leukämie (CML)  
Weiss ich nicht genau    
_________________________________ 
 




Non-Hodgkin-Lymphom        
 
Hodgkin-Lymphom        
 
Weiss ich nicht genau   
_________________________________ 
Falls Sie die genaue Diagnose in Erfahrung bringen könnten, wären wir sehr dankbar. 
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Nur wenn mehr als einer Ihrer Verwandten an einer Leukämie (Blutkrebs), 
Lymphom (Lymphdrüsenkrebs) erkrankt ist/war: 
  
Wir möchten Sie bitten für jede Personen zu der Sie angegeben haben, dass sie an 
einer der oben genannten Krankheiten erkrankt waren (sind) jeweils eine eigene Seite 
(Seite 9,10 und 11 sind identisch) auszufüllen und möglichst genaue Angaben zu 
machen: 
 
Verwandtschaftsverhältnis (z.B.  Tante mütterlicherseits):______________________ 
 
Vorname und Nr : _______________________ 
  
Kreuzen Sie bitte das Zutreffende an: 
 
 Leukämie (Blutkrebs)  
 
Wenn ja:    
 
Akute lymphatische Leukämie (ALL)      
Chronisch lymphatische Leukämie (CLL)  
 
Akute myeloische Leukämie (AML)    
Chronische myeloische Leukämie (CML)  
Weiss ich nicht genau    
_________________________________ 
 




Non-Hodgkin-Lymphom        
 
Hodgkin-Lymphom        
 
Weiss ich nicht genau   
_________________________________ 
Falls Sie die genaue Diagnose in Erfahrung bringen könnten, wären wir sehr 
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Nur wenn mehr als einer Ihrer Verwandten an einer Leukämie (Blutkrebs), 
Lymphom (Lymphdrüsenkrebs) erkrankt ist/war: 
  
Wir möchten Sie bitten für jede Personen zu der Sie angegeben haben, dass sie an 
einer der oben genannten Krankheiten erkrankt waren (sind) jeweils eine eigene Seite 
(Seite 9,10 und 11 sind identisch) auszufüllen und möglichst genaue Angaben zu 
machen: 
 
Verwandtschaftsverhältnis (z.B.  Tante mütterlicherseits):______________________ 
 
Vorname und Nr : _______________________ 
  
Kreuzen Sie bitte das Zutreffende an: 
 
 Leukämie (Blutkrebs)  
 
Wenn ja:    
 
Akute lymphatische Leukämie (ALL)      
Chronisch lymphatische Leukämie (CLL)  
 
Akute myeloische Leukämie (AML)    
Chronische myeloische Leukämie (CML)  
Weiss ich nicht genau    
_________________________________ 
 




Non-Hodgkin-Lymphom        
 
Hodgkin-Lymphom        
 
Weiss ich nicht genau   
_________________________________ 
 
Falls Sie die genaue Diagnose in Erfahrung bringen könnten, wären wir sehr dankbar. 
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Appendix-4 
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Appendix-5 
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Appendix-6            




Grundsätzlich geht der Bogen bei Angaben zur Verwandtschaft immer vom (ehemals) an 
Lymphom erkrankten Kind/Jugendlichen (Im Bild mit „Patient“ gekennzeichnet).aus. 
 
Der Fragebogen ist so aufgebaut, dass Sie zuerst nach Angaben zu dem (ehemals) an 
Lymphom erkrankten Kind und dann unter Punkt 1 zu seinen Eltern gefragt werden. 
Punkt 2 fragt nach Angaben zu Geschwistern des (ehemals) an Lymphom erkrankten Kindes. 
Hier bitten wir auch Halbgeschwister anzugeben. Darunter geben Sie im Falle von 
Halbgeschwistern an, ob dieses mit dem an Krebs erkrankten Kind den Vater oder die Mutter 
als gemeinsamen Elternteil hat. 
Unter Punkt 3 werden dann nach Angaben zu evtl. schon vorhandenen Nichten und Neffen des 
(ehemals) erkrankten Kindes gefragt. 
Punkt 4 fragt Angaben zu evtl. schon vorhandenen eigenen Kindern des (ehemals) erkrankten 
Kindes ab. 
Anschließend folgen Fragen zu den Tanten/Onkeln mütterlicherseits (Punkt 5) und die gleichen 
Fragen zu den Tanten/Onkeln väterlicherseits (Punkt 6).  
In Punkt 7 werden die Cousinen/Cousins mütterlicherseits, also die Kinder der mütterlicherseits 
vorhandenen Tanten/Onkel, abgefragt. Punkt 8 fragt die Cousinen/Cousins väterlicherseits ab. 
Sollten Verwandte abgefragt werden, die nicht existieren, streichen Sie das Feld großzügig 
durch. 
 
Zu jeder Person sollen bestimmte Angaben gemacht werden. Dies soll im Folgenden näher 
erklärt werden. In der ersten Spalte wird die jeweilige Person angegeben. Sofern es sich nicht 
um Vater oder Mutter handelt, finden Sie zur Identifizierung der Person bei Geschwistern, 
Tanten/Onkeln und Cousinen/Cousins “Vorname“ 
  





















1        
2        
 
Bitte geben Sie hier den Vornamen des Verwandten an. 
Den Vornamen erfragen wir, um im Familienstammbaum eine eindeutige Zuordnung z.B. eines 
möglicherweise ebenfalls an Krebs erkrankten Cousins über die Geschwister der Eltern 
vornehmen zu können. Die Vornamen werden nicht gespeichert sondern nur die vor dem 
Vornamen verzeichnete laufende Nummer, „Nr.“ 
 
Geburtsjahr: Bitte nennen Sie hier das Jahr, in dem die Person geboren wurde. 
 
Geschlecht: Bitte kennzeichnen Sie hier mit einem Buchstaben das Geschlecht der Person. Für 
einen männlichen Verwandten bitte „m“, für einen weiblichen Verwandten bitte „w“ eintragen. 
 
Kind von Tante/Onkel / Kind von Geschwister: Dies ist ein Sonderfeld was nur bei den Punkten 
3, 7 und 8 auftaucht. Hier soll für beispielsweise die Cousinen (Punkte 7 und 8) angegeben 
werden, wessen Kind sie sind. Das heißt, dass beispielsweise unter Punkt 5 die Tanten/Onkel 
abgefragt worden sind und laufende Nummern bekommen haben. Unter Punkt 7 würden Sie 
dann beispielsweise Kinder von diesen Tanten/Onkel auflisten. Damit klar ist, welches Kind zu 
welcher Tante/Onkel gehört, bitten wir hier die entsprechende laufende Nummer des 
Tante/Onkels und dessen Vornamen einzuschreiben. 
Das Gleiche gilt für die Nichten und Neffen unter Punkt 3. Hier dann die laufenden Nummern 
der Geschwister aus Punkt 2 angeben, zu denen die Nichten und Neffen gehören. 
 
In der Spalte „Krebs“ sollen Sie Angaben machen, ob die entsprechende Person an einer 
Krebsart erkrankt ist.  Ist die Person bis zum Zeitpunkt der Befragung nicht an Krebs erkrankt, 
ist hier „nein“ zu beantworten. 
 
„Jahr der Diagnose“: Bitte tragen Sie hier das Jahr ein, indem der Krebs bei der Person 
entdeckt wurde. Sofern Sie im Falle einer Krebserkrankung das genaue Jahr der Erkrankung 
nicht kennen, geben Sie bitte ungefähr das Alter an, in dem der Familienangehörige erkrankte 
und vermerken Sie dies bitte handschriftlich 
 
Immunabwehrschwäche: Geben Sie hier bitte an, ob bei der betreffenden Person eine 
Abwehrschwäche als Krankheit bekannt ist und wenn ja welche. Damit ist jedoch nicht eine 
allgemeine Anfälligkeit z.B. für Infektionen gemeint. Als Immunabwehrschwäche gilt nur eine 
Krankheit, die von einem Arzt festgestellt wurde. In diesem Falle geben Sie bitte, sofern Ihnen 
bekannt, die genaue Diagnose an, z.B. Antikörpermangel-Syndrom. Wenn Ihnen die genaue 
Diagnose nicht bekannt ist, geben Sie bitte nur an „ja“. Liegt keine von einem Arzt festgestellt 
Abwehrschwäche vor, geben Sie bitte an „nein“. Auf Seite 4 dieser Anleitung finden Sie eine 
Liste der wichtigsten und häufigsten Immunabwehrschwächen, die in Frage kommen 
können.  
  





Nach dieser kleinen Tabelle folgt folgendes Feld: 
 „Nur falls sie bei Krebs „ja“ angegeben haben.  
 
Nr. & Vorname Genaue Diagnose 
  
  
Haben Sie Leukämie, Lymphdrüsenkrebs, Lymphom o.ä. eingegeben? Dann füllen Sie bitte im 
Anhang Seite 9 aus. 
__________________________________________________________________________ 
 
In diesem Feld werden Sie gebeten, die Krebsdiagnose so genau wie möglich zu beschreiben. 
„Bitte tragen Sie hier ein, an welcher Art von Krebs das Familienmitglied erkrankt ist. Wir bitten 
hier möglichst genaue Angaben zu machen. Falls Sie die genaue Diagnose nicht kennen, wäre 
es gut, wenn Sie zumindest angeben könnten, ob es ein Tumor, eine Leukämie oder 
Lymphkrebs war. Wenn Sie auch dies nicht wissen, sondern lediglich, dass die Person an 
Krebs erkrankt ist/war, geben Sie bitte an „genaue Diagnose nicht bekannt“. 
 
Falls Sie wissen, dass es sich bei dem Krebs um eine Leukämie (Blutkrebs) oder ein 
Lymphom (Lymphdrüsenkrebs) handelt, finden Sie im Anhang des Fragebogens (ab Seite 
9) eine kurze genaue Rückfrage zu dieser an Leukämie oder Lymphom erkrankten Person. 
Wir möchten Sie bitten für jede Personen zu der Sie angegeben haben, dass sie an einer der 
oben genannten Krankheiten erkrankt waren (sind) jeweils eine eigene Seite (Seite 9,10 und 11 
sind identisch) auszufüllen und möglichst genaue Angaben zu machen: 
 
Seite 9 und folgende: 




In jedem Unterblock des Fragebogens finden Sie folgende wichtige Frage: 
(z.B.: bei der Abfrage nach Tanten/Onkel, wenn ein Onkel und eine Tante verstorben sind:) 
 
Ist ein(e) Tante / Onkel des Patienten mütterlicherseits verstorben? 
 nein  ja   , und zwar (Vorname/Nr): Konrad 1, Sybille 4 
. 
  Todesjahr (Tante/Onkel Nr.|_1_|): I_1_|_9_I_7_I_3_I  
 Todesjahr (Tante/Onkel Nr.|_4_|): I_2_|_0_I_0_I_1_I 
 
Bitte kreuzen Sie unbedingt an, ob jemand der gerade abgefragten Personen 
verstorben ist oder nicht! 
 
Dabei ist es nicht wichtig, ob die Person an Krebs oder z.B. einem Unfall verstorben ist. Bitte 
spezifizieren sie im Abschnitt darunter, welche der aufgelisteten Person(en) verstorben ist (sind) 
mit angegebenem Name und der laufenden Nummer. Bitte füllen Sie anschließend die Abfrage 
nach dem Todesjahr aus und geben Sie auch hier wieder die laufende Nummer des 
Verwandten an. 
Diese Angaben benötigen wir, um die Gesamt-Lebensjahre aller in dem Bogen erfragten 
Familienmitglieder berechnen zu können.  
 
  





Sollten die im Fragebogen vorgesehenen Zeilen z.B. für die Cousinen/Cousins nicht 
ausreichen, bitten wir Sie uns auf einem einfachen Schreibpapier nach dem Muster der Tabelle 
die Angaben zu den weiteren Familienmitgliedern aufzuzeichnen und dieses Blatt dem 




















Common variable Immunschwäche 
Bloom Syndrom 
Ataxia teleangiectatica 
Nijmegen Breakage (Chromosomen-Instabilitäts) Syndrom 
Andere Chromosomen Bruchsyndrome 
Fanconi Anämie 
DiGeorge Syndrom  
Wiskott-Aldrich Syndrom 
T-Zell Mangel Syndrom 
Schwerer kombinierter Immundefekt (SCID) 
ADA (Adenosindeaminase) Mangel 
PNP (Nukleosidphosphorylase) Mangel 
Schwachman Syndrom 
Kostman Syndrom (angeborene Agranulozytose) 
 
 
Erworbene Immunschwäche Erkrankungen 
 
AIDS (HIV-Infektion) 
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Checkliste 
(NUR Für Sie, als Hilfe nach dem Ausfüllen.  Muss nicht zurückgesandt werden) 
 
Haben Sie den Bogen fertig ausgefüllt?  
Herzlichen Dank, dass Sie sich die Mühe gemacht haben! 
Anhand dieser Checkliste könnten Sie für sich den Bogen noch einmal durchgehen und 
schauen, ob noch Lücken bestehen. Aufgelistet sind 10 Punkte, bei denen im Probelauf häufig 
Flüchtigkeitsfehler aufgetreten sind. 
 
Punkt 1: Eltern des Patienten 
 




Punkt 2: Geschwister des Patienten: 
 
Haben Sie angekreuzt, ob ein Geschwister des Kindes/Patienten verstorben ist?   
_________________________________________________________________________ 
 
Punkt 3: Kinder von Geschwistern des Patienten (Nichten/Neffen): 
 
1. Bitte tragen Sie, das jeweilige Geburtsjahr ein!          
2. Haben Sie angekreuzt, ob ein(e) Nichte/Neffe des Kindes/Patienten verstorben 
 ist?                    
3. Wenn ein(e) Nichte/Neffe verstorben ist, stellen Sie sicher, dass Sie diese(n) auch in der 
Tabelle mit Geburtsjahr und Krebs ja/nein aufgelistet haben.      
__________________________________________________________________________ 
 
Punkt 4: Leibliche Kinder des Patienten: 
 






Punkt 5: Tanten/Onkel des Kindes/Patienten mütterlicherseits: 
 
1. Bitte tragen Sie, das jeweilige Geburtsjahr ein!          
2. Haben Sie angekreuzt, ob ein(e) Tante/Onkel des Kindes/Patienten verstorben 
 ist?                    
3. Wenn ein(e) Tante/Onkel verstorben ist, stellen Sie sicher, dass Sie diese(n) auch in der 
Tabelle mit Geburtsjahr und Krebs ja/nein aufgelistet haben.      
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Punkt 6: Tanten/Onkel des Kindes/Patienten väterlicherseits: 
 
1. Bitte tragen Sie, das jeweilige Geburtsjahr ein!          
2. Haben Sie angekreuzt, ob ein(e) Tante/Onkel des Kindes/Patienten verstorben 
 ist?                    
3. Wenn ein(e) Tante/Onkel verstorben ist, stellen Sie sicher, dass Sie diese(n) auch in der 
Tabelle mit Geburtsjahr und Krebs ja/nein aufgelistet haben.      
__________________________________________________________________________ 
 
    Cousinen/Cousins 
 
Punkt 7: Leibliche Cousinen/Cousins des Kindes/Patienten mütterlicherseits: 
 
1. Bitte tragen Sie, das jeweilige Geburtsjahr ein!          
2. Haben Sie angekreuzt, ob ein(e) Cousin/Cousine des Kindes/Patienten verstorben 
ist?                     
3. Wenn ein(e) Cousin/Cousine verstorben ist, stellen Sie sicher, dass Sie diese(n) auch in 
der Tabelle mit Geburtsjahr und Krebs ja/nein aufgelistet haben.     
 
 
Punkt 8: Leibliche Cousinen/Cousins des Kindes/Patienten väterlicherseits: 
 
1. Haben Sie angekreuzt, ob ein(e) Cousin/Cousine des Kindes/Patienten verstorben 
ist?                     
2. Wenn ein(e) Cousin/Cousine verstorben ist, stellen Sie sicher, dass Sie diese(n) auch in 
der Tabelle mit Geburtsjahr und Krebs ja/nein aufgelistet haben.     
3. Wenn ein(e) Cousin/Cousine verstorben ist, stellen Sie sicher, dass Sie diese(n) auch in 
der Tabelle mit Geburtsjahr und Krebs ja/nein aufgelistet haben.     
 
 
Anhang: Haben Sie, falls eine oder mehrere Personen an Leukämie (Blutkrebs) oder einem 




Herzlichen Dank für Ihre Mitarbeit, Sie haben uns sehr geholfen!! 
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Appendix-7  
Information für Teilnehmer an einer Umfrage 
 
Titel der Studie: 
‚NHL-2007 – Gibt es eine familiäre Veranlagung für Non- Hodgkin- Lymphome 
im Kinder- und Jugendalter?’  
 
 
Liebe Patientin, lieber Patient, liebe Eltern, 
diese Informationsschrift soll dazu dienen, Sie über eine wissenschaftliche  Studie aufzuklären 
und Sie um Ihre Mithilfe bei der Durchführung dieser Untersuchung zu bitten. 
Bevor Sie sich dafür entscheiden, beiliegenden Fragebogen auszufüllen, lesen Sie bitte diese 
Patienteninformation sorgfältig. Sie beschreibt Einzelheiten der Studie, unsere Ziele und was 
von Ihnen bei einer Teilnahme erwartet wird. 
 
Hintergrund 
Die genauen Ursachen und Entstehungsmechanismen von Krebs bei Kindern und Jugendlichen 
sind bis heute weitestgehend unbekannt, wobei einige Studienergebnisse vermuten lassen, 
dass eine Häufung von Krebserkrankungen in Familien an Krebs erkrankter Kinder und 
Jugendlicher möglich ist. Dies könnte auf eine gewisse Veranlagung für Krebserkrankungen 
hinweisen. Die Kenntnis von  familiär prädisponierenden Faktoren könnte für künftige 
Patientengenerationen von Nutzen sein, zum Beispiel eine frühere Erkennung und damit eine 
bessere Heilungschance möglich machen. Unsere Forschungsgruppe an der Universität 
Gießen hat sich in Kooperation mit dem Deutschen Kinderkrebsregister vorgenommen in einer 
epidemiologischen Studie diese Frage für eine der häufigsten Krebserkrankungen bei Kindern 
und Jugendlichen, einer Form des Lymphknotenkrebses, zu überprüfen; „Gibt es eine familiäre 
Veranlagung für die Entstehung von Non-Hodgkin-Lymphomen (NHL) im Kindesalter?“ Für 
diese Untersuchung wollen wir die Familien der etwa 2500 Kinder und Jugendlichen aus 
Deutschland ansprechen, die seit 1986 in den Therapiestudien zur Behandlung von Kindern 
und Jugendlichen mit Non-Hodgkin- Lymphomen behandelt und registriert wurden. 
Sollte sich eine familiäre Häufung bestätigen, so könnte man im Detail verfolgen, welche 
Krebserkrankungen eventuell in besonderem Zusammenhang zum Non-Hodgkin-Lymphom im 
Kindesalter stehen und ob bestimmte Zellveränderungen vererbt werden. 
Bei Kenntnis eines erhöhten Risikos in der Familie könnten erkrankte Kinder frühzeitig erkannt 
und damit leichter behandelt werden.  
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Das betroffene Kind könnte im Frühstadium mit einer verhältnismäßig moderaten Therapie 
geheilt werden, während das NHL im fortgeschrittenen Stadium eine sehr viel aggressivere 
Therapie - bei geringerer Heilungschance - erfordert. 
Mit Ihrer Hilfe könnte der wichtige Grundstein gelegt werden, Hochrisikogruppen ausfindig zu 
machen und Kinder frühzeitig zu behandeln. 
 
Beiliegend haben Sie einen Fragebogen erhalten, mit dem die wesentlichen Informationen 
erfragt werden sollen, die für die Beantwortung dieser Fragestellung erforderlich sind. In dem 
Fragebogen wird im Wesentlichen abgefragt, ob es in der näheren Verwandtschaft des an 
Lymphom erkrankten Kindes/Jugendlichen besonders oft oder besonders früh zu bösartigen 
Erkrankungen (Krebs) gekommen ist.  
 
Ziele unserer Studie: 
 Überprüfung einer familiären Häufung von bösartigen Erkrankungen (Krebs) 
 Dadurch Identifizierung von Risikogruppen  
 Grundstein legen für Methoden zur frühzeitigen NHL-Erkennung in Risikogruppen 
 
Die Teilnahme - Worum möchten wir Sie bitten? 
Wir möchten Sie bitten, den anonymen Bogen einmalig vollständig auszufüllen und mit 
beiliegendem frankierten, adressierten Rückumschlag zurück zu senden.  
Wir rechnen damit, dass sich eine Häufung von malignen Erkrankungen im Bereich der 
hämatogenen (das Blut bildende System betreffenden) Erkrankungen finden könnte. 
Sollte ein Familienmitglied an Non-Hodgkin-Lymphom, Leukämie oder Ähnlichem erkrankt sein, 
würden wir uns erlauben, eventuell nochmals detaillierter nachzufragen. 
Zum Vergleich werden wir auch bei einer zufälligen Stichprobe der übrigen Teilnehmer an 
dieser Studie nochmals genauer nachfragen. Sollten Sie eine der wenigen Familien sein, die 
nochmals kontaktiert werden, haben Sie dann selbstverständlich erneut die Möglichkeit sich für 
oder gegen eine Teilnahme zu entscheiden. 
 
Können Sie aus der Studie wieder ausscheiden?  
Die Teilnahme an dieser Studie erfolgt auf freiwilliger Basis. Wenn Sie nicht daran teilnehmen 
wollen, senden Sie den Bogen nicht zurück und Sie brauchen dann überhaupt nichts Weiteres 
zu unternehmen. Auch dann, wenn Sie den Fragebogen zurücksenden, können Sie Ihre 
Einwilligung zur Teilnahme an dieser Studie jederzeit ohne Angabe von Gründen zurückziehen. 
Durch die Nichtteilnahme entstehen Ihnen keine Nachteile. 
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Wenn Sie sich zur Teilnahme entschließen, möchten wir Sie bitten, den Fragebogen möglichst 
innerhalb von 4 Wochen ausgefüllt in dem beiliegenden, frankierten und adressierten 
Umschlag zurückzusenden. 
 
Wie vertraulich werden die ermittelten Daten behandelt?  
Die Angaben, die Sie im Fragebogen machen, werden nach den Bestimmungen des 
Bundesdatenschutzgesetzes streng vertraulich behandelt und nur ohne Angabe der Namen 
(d.h. pseudonymisiert) gespeichert und ausgewertet. 
Beim Umgang mit den Krankheitsdaten und im Rahmen der statistischen Auswertung und 
Veröffentlichung der Studienergebnisse werden die Grundsätze des Datenschutzes und der 
ärztlichen Schweigepflicht beachtet. Es ist geplant, dass die Auswertungen der 
Studienergebnisse in Fachzeitschriften veröffentlicht werden. Dabei werden nur 
zusammengefasste und verschlüsselte Daten dargestellt. 
 
Allgemeines 
Anbei finden Sie eine kurze Anleitung, die Ihnen die einzelnen Felder des Fragebogens  erklärt 
und Ihnen beim Ausfüllen des Bogens helfen soll. 
Am Anfang des Fragebogens finden Sie eine Einverständniserklärung. Bitte unterschreiben Sie 
diese, da wir Ihre Daten sonst nicht auswerten dürfen. 
 
Wir danken Ihnen für Ihren wichtigen Beitrag! 
 
Prof. Dr. Alfred Reiter         Dr. Peter Kaatsch 
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